DynPort Vaccine Company LLC, A GDIT Company
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously
Role: collaborator
A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly
Role: collaborator
Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
Role: lead
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
Role: lead
Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine
Role: lead
Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults
Role: lead
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
Role: lead
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
Role: lead
Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®
Role: lead
A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
Role: lead
Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V
Role: lead
All 11 trials loaded